Literature DB >> 413012

Gentamicin-resistant Pseudomonas aeruginosa: Mayo Clinic Experience, 1970-1976.

T F Keys, J A Washington.   

Abstract

During the period 1970 through 1976, there were 144 patients from whom gentamicin-resistant Pseudomonas aeruginosa (minimum inhibitory concentration [MIC], more than 5 microgram/ml) was isolated. In 20(21 percent) of the 95 patients who acquired such organisms within our institutions, the occurrence was considered clinically significant. Factors that favored the appearance of gentamicin-resistant P. aeruginosa included prolonged hospitalization, previous antibiotic treatment, increased gentamicin usage, underlying disease, and instrumentation (70 percent). Virulence of gentamicin-resistant isolates appeared less than that of susceptible organisms, with bacteremia due to these isolates occurring in only three cases. Resistant isolates with MICs for gentamicin of 8 to 16 microgram/ml were more susceptible to tobramycin than to amikacin, whereas isolates with MICs for gentamicin of 64 microgram/ml or greater were more susceptible to amikacin than to tobramycin. Eighty percent of all strains were susceptible to 128 microgram/ml or less of carvenicillin. Favorable results occurred in 12 or 13 cases treated with gentamicin plus carbenicillin, whereas treatment with either of these agents alone resulted in failure or relapse in 7 of 14 cases.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 413012

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  6 in total

Review 1.  Virulence versus resistance.

Authors:  K M Krasinski
Journal:  Bull N Y Acad Med       Date:  1987-04

Review 2.  An overview of nosocomial infections, including the role of the microbiology laboratory.

Authors:  T G Emori; R P Gaynes
Journal:  Clin Microbiol Rev       Date:  1993-10       Impact factor: 26.132

3.  Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. The Endotracheal Tobramycin Study Group.

Authors:  R B Brown; J A Kruse; G W Counts; J A Russell; N V Christou; M L Sands
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

4.  Phenotypic factors correlated with the absence of virulence among gentamicin-resistant Pseudomonas aeruginosa strains.

Authors:  R B Clark; J M Janda; E J Bottone
Journal:  J Clin Microbiol       Date:  1984-08       Impact factor: 5.948

5.  Aminoglycoside resistance among Pseudomonas aeruginosa isolates with an unusual disk diffusion antibiogram.

Authors:  R B Clark; C C Sanders; C B Pakiz; M K Hostetter
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

6.  Gentamicin-resistantPseudomonas aeruginosa: Concepts regarding their evolution and attenuated virulence.

Authors:  J M Janda; D J Sheehan; A Das; E J Bottone
Journal:  Microb Ecol       Date:  1982-12       Impact factor: 4.552

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.